In this partially randomized clinical trial, the authors find that an orally inhaled Ad5-nCoV booster is associated with a lower incidence of symptomatic COVID-19 during the following 6 months compared with controls who haven’t received a booster. Intramuscular administered Ad5-CoV booster is associated with reduced COVID-19 incidence as well.
- Siyue Jia
- Yuanbao Liu
- Jingxin Li
